Teriparatide: Physiology and What Research Reports

What Teriparatide Is

Teriparatide is a recombinant peptide corresponding to the first 34 amino acids of human parathyroid hormone, often written as PTH(1–34). That N-terminal fragment carries the receptor-binding region of the full 84-amino-acid hormone, so the shortened peptide retains the ability to activate the PTH type 1 receptor on osteoblasts and renal tubular cells. In the peptide literature it is one of the most frequently studied examples of a hormone fragment developed into an approved drug, which is why it appears repeatedly in discussions of endogenous peptide analogues.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment. Nothing here describes a protocol, and no dose is presented except where a cited study used it.

Where the Parent Hormone Is Produced

Parathyroid hormone is synthesised and secreted by the chief cells of the four parathyroid glands, which sit behind the thyroid. Secretion is governed by the calcium-sensing receptor: falling ionised calcium increases PTH release. PTH then raises serum calcium by increasing osteoclastic bone resorption indirectly through osteoblast signalling, increasing renal calcium reabsorption, reducing phosphate reabsorption, and stimulating 1α-hydroxylase so that more 1,25-dihydroxyvitamin D is formed and intestinal calcium absorption rises. Teriparatide reproduces the signalling end of that system without reproducing the gland's feedback control.

Continuous Versus Intermittent Signalling

The best-known feature of PTH physiology is that the same receptor produces opposite skeletal outcomes depending on exposure pattern. Continuously elevated PTH, as in primary hyperparathyroidism, is associated with net bone loss, particularly cortical bone. Intermittent, short-lived receptor activation instead favours osteoblast survival and bone formation, which is the pharmacological rationale behind studying teriparatide as an anabolic rather than antiresorptive agent. A review of teriparatide indications beyond osteoporosis described this anabolic profile as the basis for investigating the peptide in a range of skeletal conditions (PMID 22629497).

How It Is Measured and Studied

Research on teriparatide rarely measures the peptide itself in circulation. Instead, studies typically track downstream physiology and structure:

• Bone mineral density (BMD) by dual-energy X-ray absorptiometry at the spine, total hip and femoral neck.
• Bone turnover markers such as formation and resorption markers in serum.
• Radiographic or CT endpoints such as fracture union and arthrodesis fusion.
• Biochemical endpoints such as serum and urinary calcium in parathyroid disorders.
• Pharmacovigilance databases, which catalogue reported adverse events across large post-marketing populations.

Randomised and Comparative Evidence in Osteoporosis

A systematic review and meta-analysis of randomised controlled trials compared teriparatide with bisphosphonates, and denosumab with bisphosphonates, in osteoporosis populations not previously treated with bisphosphonates, and the researchers analysed efficacy and safety outcomes across those trials (PMID 39312040). Sequence and combination questions were examined in the DATA-Switch extension of a randomised controlled trial, which studied transitions between denosumab and teriparatide in postmenopausal osteoporosis and reported that the order in which the two agents were given influenced bone mineral density outcomes (PMID 26144908). A 2025 report examined daily teriparatide in glucocorticoid-induced osteoporosis among rheumatic disease patients who had switched from bisphosphonate therapy, and the study assessed effectiveness in that switched population (PMID 40385888).

Contexts Studied Beyond Osteoporosis

Fracture Healing and Fusion

Because the peptide acts on osteoblast biology, several investigators have examined whether it affects bone healing. A report in Translational Medicine @ UniSa examined teriparatide in fracture non-unions, describing its use where fractures had failed to unite (PMID 26535187). A separate study evaluated effects of teriparatide on fusion rates in patients undergoing complex foot and ankle arthrodesis, reporting fusion outcomes in that surgical population (PMID 31690528).

Hypoparathyroidism

When the parathyroid glands are absent or non-functional, replacing the hormone signal rather than supplementing calcium and vitamin D has been investigated. A clinical report described chronic hypoparathyroidism managed with teriparatide and discussed biochemical control in that setting (PMID 33538953). At the extreme end of the age range, a case report described teriparatide therapy in a 4-month-old infant with severe hypoparathyroidism (PMID 35002563).

Laboratory Work

Cell-level research has also examined the peptide. An in vitro study reported a protective effect of teriparatide against vancomycin-induced cytotoxicity in osteoblasts, examining osteoblast viability in the presence of the antibiotic (PMID 36371341).

Adverse Events: What Studies Report

Post-marketing and case literature describes several categories of reported event. A disproportionality analysis of the FDA Adverse Event Reporting System examined indications and adverse events associated with teriparatide across reported cases, and the researchers catalogued signals present in that database (PMID 39170708). Rarer events have been described individually: a case series reported teriparatide-associated calciphylaxis (PMID 34494145), and a case report described teriparatide-induced atrial tachycardia in a single patient (PMID 29487102). Case reports describe what happened in one person and cannot establish how often an event occurs; the meta-analysis of randomised trials remains the higher-tier source for comparative safety (PMID 39312040).

Study Types at a Glance

Why the Term Comes Up in Peptide Reading

Teriparatide is frequently cited as a worked example of how an endogenous peptide hormone can be truncated to its active fragment and developed as a regulated pharmaceutical. It is a prescription medicine, not a research chemical, and the literature summarised above concerns supervised clinical and laboratory settings. Readers who encounter the name in peptide contexts are usually meeting it as an illustration of receptor pharmacology — specifically that dosing pattern, not just molecule identity, determines biological outcome.

References

• Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial (Lancet, 2015)
• Teriparatide-associated calciphylaxis: a case series (Osteoporosis International, 2022)
• Teriparatide-induced atrial tachycardia (BMJ Case Reports, 2018)
• Teriparatide Therapy in a 4-Month-Old With Severe Hypoparathyroidism (Journal of Pediatric Pharmacology and Therapeutics, 2022)
• Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials (Archives of Osteoporosis, 2024)
• Teriparatide in Fracture Non-Unions (Translational Medicine @ UniSa, 2015)
• Chronic hypoparathyroidism and treatment with teriparatide (Endocrine, 2021)
• Effects of teriparatide on fusion rates in patients undergoing complex foot and ankle arthrodesis (Foot and Ankle Surgery, 2020)
• Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS) (Frontiers in Pharmacology, 2024)
• Effectiveness of Daily Teriparatide in Managing Glucocorticoid-Induced Osteoporosis in Rheumatic Disease Patients After Switching From Bisphosphonate Therapy (Cureus, 2025)
• Teriparatide - Indications beyond osteoporosis (Indian Journal of Endocrinology and Metabolism, 2012)
• Protective effect of teriparatide against vancomycin-induced cytotoxicity in osteoblasts (Journal of Orthopaedic Science, 2023)